Showing 2651-2660 of 5646 results for "".
- Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEOhttps://modernod.com/news/second-sight-announces-departure-of-will-mcguire-president-and-ceo-and-appointment-of-gregg-williams-as-acting-ceo/2477384/Second Sight Medical Products announced the departure of Will McGuire, President and Chief Executive Officer, effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board. Effective March 27, 20
- Reichert Technologies Signs Exclusive Deal for CATS Reusable Tonometer Prismshttps://modernod.com/news/reichert-technologies-signs-exclusive-deal-for-cats-reusable-tonometer-prisms/2477372/Reichert Technologies has announced its exclusive partnership with CATS Tonometer to distribute the CATS Reusable Tonometer Prism in the United States. The patented CATS Tonometer Prism is superior in IOP accuracy to traditional Goldmann prism, according to a company news release. “For dec
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2020 Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2020-annual-conference/2477365/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 10-11) and 29th annual General Conference (September 12-13) at the Hyatt Regency Columbus in Columbus, Ohio. “This year’s conference them
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Iridex Launches Revised MicroPulse P3 Device for Glaucomahttps://modernod.com/news/iridex-launches-revised-micropulse-p3-device-for-glaucoma/2477328/Iridex announced the introduction of the second generation of the MicroPulse P3 Device, which has been redesigned to deliver greater stability, visualization, coupling, and fit, according to a company news release. “The revised MicroPulse P3 Device is intuit
- Novartis Launches Review Into Safety of Eye Drug Beovuhttps://modernod.com/news/novartis-launches-review-into-safety-of-eye-drug-beovu/2477324/Novartis has launched an external review into the safety of its wet AMD drug Beovu after the American Society of Retinal Specialists (ASRS) raised concerns, according to a Reuters
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Study Advances Development of Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/study-advances-development-of-gene-therapy-for-x-linked-retinitis-pigmentosa/2477321/A new study marks a significant advance in developing a gene therapy for X-linked retinitis pigmentosa, a hereditary disease that leads to severe sight loss in young males. Researchers at Bascom Palmer Eye Institute, the Department of Ophthalmology a
- Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025https://modernod.com/news/expanding-product-needs-surgery-growth-will-drive-retinal-surgical-device-market-to-nearly-2-billion-by-2025/2477308/Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retinal surgical device market is expected to total more than $1.57 billion in 2020, with revenue rising
- Ocular Therapeutix Presents Data Demonstrating a Reduction in IOP in Patients Treated with OTX-TIChttps://modernod.com/news/ocular-therapeutix-presents-data-demonstrating-a-reduction-in-iop-in-patients-treated-with-otx-tic/2477290/Ocular Therapeutix presented data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension. Data from this phase 1 clinical trial demonstrated a clinically-meaningful reduction in IOP for up to 18 months in the